Comparative Pharmacology
Head-to-head clinical analysis: AXID versus PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXID versus PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER.
AXID vs PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive, reversible inhibition of histamine at H2-receptors on gastric parietal cells, reducing gastric acid secretion by blocking the H2-receptor-mediated activation of adenylate cyclase and subsequent cAMP production.
Competitive histamine H2-receptor antagonist; inhibits gastric acid secretion by blocking H2 receptors on parietal cells.
300 mg orally once daily at bedtime or 150 mg orally twice daily. Max 300 mg/day.
20 mg intravenously every 12 hours; or 40 mg intravenously once daily. For Zollinger-Ellison syndrome, initial dose 20 mg intravenously every 6 hours; adjust based on acid output.
None Documented
None Documented
1.5-2.5 hours (prolonged in renal impairment: up to 4-5 hours if CrCl <20 mL/min)
2.5–3.5 hours in normal renal function; prolonged to 6–8 hours in moderate renal impairment (CrCl <50 mL/min) and up to 20 hours in severe renal failure (CrCl <10 mL/min)
Renal (60% unchanged), biliary (30%), fecal (<10%)
Renal (65–70% unchanged via tubular secretion and glomerular filtration); biliary/fecal (minor, <10%)
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist